2021 Annual Meeting | C64 - Genetic Therapies for Neurological Diseases: Today and Tomorrow

Date Tuesday 04/20/21

Time 02:00 PM - 03:00 PM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Robert C. Griggs, MD, FAAN

Topic(s) General Neurology

Learning Objectives Participants should become familiar with the diseases currently amenable to genetic therapies as well as still uncertain questions about their use, their durability, and their availabilty to all demographic groups. Participants should also gain an overview of the prospects for future novel treatments of other diseases.

CME Available 1.00 CME credit

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
02:00 PM - 02:15 PM EDT	Speaker	Overview of Gene Therapies: Approved treatments Petra Kaufmann, MD, FAAN
02:15 PM - 02:30 PM EDT	Speaker	Neuromuscular Diseases: Today and Tomorrow Jerry R. Mendell, MD, FAAN
02:30 PM - 02:40 PM EDT	Speaker	FDA Perspective Wilson W. Bryan, MD
02:40 PM - 03:00 PM EDT	Discussion	Approval and Implementation Robert C. Griggs, MD, FAAN, Jerry R. Mendell, MD, FAAN, Petra Kaufmann, MD, FAAN, Wilson W. Bryan, MD

Faculty Disclosures
Robert C. Griggs, MD, FAAN	Dr. Griggs has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Strongbridge Pharmaceuticals. Dr. Griggs has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Idera Pharmaceuticals. Dr. Griggs has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Solid Biopharma. Dr. Griggs has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Santhera Pharmaceuticals. Dr. Griggs has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Griggs has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Lippincott. The institution of Dr. Griggs has received research support from PTC Pharmaceuticals. The institution of Dr. Griggs has received research support from Sarepta Pharmaceuticals. The institution of Dr. Griggs has received research support from National Institutes of Health. The institution of Dr. Griggs has received research support from Santhere Pharmaceuticals. Dr. Griggs has received personal compensation in the range of $500-$4,999 for serving as a Study section member with National Institutes of Health. Dr. Griggs has a non-compensated relationship as a Board of Directors;Chair Research Advisory Committee with American Brain Foundation that is relevant to AAN interests or activities.
Jerry R. Mendell, MD, FAAN	Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta Therapeutics . The institution of Dr. Mendell has received research support from Sarepta.
Petra Kaufmann, MD, FAAN	Dr. Kaufmann has received personal compensation for serving as an employee of Novartis Gene Therapies. Dr. Kaufmann has received personal compensation for serving as an employee of Affinia Therapeutics.
Wilson W. Bryan, MD	Dr. Bryan has received personal compensation in the range of $100,000-$499,999 for serving as a Director, Office of Tissues and Advanced Therapies with United States Food and Drug Administration (FDA).